Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Santen Curbs Cosopt Mini Shipments after Quake, Nitto Medic to Re-Supply All Products
January 12, 2024
- Japan Ethical Drug Sales Up 2.2% in November: Crecon
January 12, 2024
- Sawai Further Delays Manufacturing Start at Trust Pharmatech Unit
January 11, 2024
- Maruho Nabs Japan Rights to AOBiome’s Eczema Drug
January 11, 2024
- New LLP Coverage Rule Loathed by Off-Patent Drug Makers but Innovative Players Hail Reform
January 10, 2024
- FDA Rejects Astellas’ Gastric Cancer Med over Manufacturing Issues
January 10, 2024
- Shionogi, NTT Data to Build Distribution Platform for Digital Therapeutics
January 10, 2024
- Quake Causes Eye Drug Maker to Stop Shipments Except Refrigerated Meds
January 10, 2024
- MTX Detoxifying Agent Megludase Finally Available in Japan
January 10, 2024
- Leqembi Now Approved in China: Eisai/Biogen
January 10, 2024
- BioCryst Japan to First Focus on Orladeyo Promotion, Eager to Set Up Own Sales Team: Local Head
January 9, 2024
- Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
- Organon Japan Gets Approval for Fertility Med Follistim after Re-Filing
January 9, 2024
- Trelegy Frontrunner in GP Promotion, Dayvigo Defends Title in HP List in October: Intage
January 9, 2024
- Boehringer Grabs Rights to Kyowa Kirin’s Fibro-Inflammatory Disease Drug
January 9, 2024
- US FDA Accepts Stelara Biosimilar for Review: Meiji
January 9, 2024
- Equa, Betanis and More Brands Gird for Generic Entry in 2024; Xarelto Contenders Too?
January 5, 2024
- After New Year’s Quake, Wholesalers See Challenges in Drug Delivery to North Part of Noto Peninsula
January 5, 2024
- Moderna Seeks Japan Nod for Pre-Filled Syringe Form of COVID Vaccine
January 5, 2024
- After GCP Scandal, Medipharma Begins Bankruptcy Proceedings
January 5, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…